The Latest in FDA Evaluations and Research

FDA News


Latest News from FDA News
EOS imaging (Euronext, FR0011191766 – EOSI), pioneer in 2D/3D orthopedic medical imaging, is today announcing its 2014 consolidated interim results for the six months ended June 30, 2014, as approved by the Board of Directors on August 29, 2014.
Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a leading Canadian specialty pharmaceutical company, announced today that it has entered into an asset purchase agreement with Orphan Canada Inc. ("Orphan") related to the Canadian rights for ATryn® and PHOTOFRIN® (porfimer sodium), two i...
Knight Therapeutics Inc. (TSX:GUD) ("Knight"), a leading Canadian specialty pharmaceutical company, announced today that it has entered into an asset purchase agreement with Orphan Canada Inc. ("Orphan") related to the Canadian rights for ATryn® and PHOTOFRIN® (porfimer sodium), two in...
SAN DIEGO, Sept. 2, 2014 /PRNewswire/ -- MEI Pharma, Inc. (Nasdaq: MEIP), an oncology company focused on the clinical development of novel therapies for cancer, announced today that it has completed enrollment in a randomized Phase II clinical trial of its lead investigational drug can...
THOUSAND OAKS, Calif., Sept. 2, 2014 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the submission of a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) via the centralized procedure for talimogene laherparepvec seeking approval for the treatment of...
Advanced Biological Laboratories (ABL), S.A, and Mayo Medical Laboratories have announced a collaboration agreement to develop a deep-sequencing pipeline for novel diagnostic laboratory-developed tests. The novel tests will be validated using clinical...
SEATTLE, Sept. 2, 2014 /PRNewswire/ -- VentiRx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company committed to the development and commercialization of novel Toll-like receptor 8 (TLR8) immunotherapies, today announced an update on corporate and clinical activities at th...
SAN DIEGO, Sept. 2, 2014 /PRNewswire/ -- Mast Therapeutics, Inc. (NYSE MKT: MSTX) today announced that the Company's Chief Executive Officer, Brian M. Culley, will present at the Rodman and Renshaw 16th Annual Global Investment Conference on Tuesday, September 9, 2014 at 2:55 p.m. East...
LAWRENCEVILLE, N.J., Sept. 2, 2014 /PRNewswire/ -- Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced that the first patient has been enrolled in its pivotal Phase III OPTIMA Study of ThermoDox® in combination with optimized radiofrequency ablatio...
SAN DIEGO, Sept. 2, 2014 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that the US Food and Drug Administration (FDA) has granted orphan drug status to APD811 for the treatment of pulmonary arterial hypertension.
SAN DIEGO, Sept. 2, 2014 /PRNewswire/ -- Orexigen Therapeutics, Inc. (Nasdaq: OREX) today announced that the U.S. Patent and Trademark Office (PTO) has issued a patent related to NB32, the Company's investigational medication being evaluated for weight loss. NB32 is a fixed-dose combin...
THOUSAND OAKS, Calif., Sept. 2, 2014 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the submission of a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) via the centralized procedure for evolocumab seeking approval for the treatment of high choleste...
MOUNTAIN VIEW, Calif., Sept. 2, 2014 /PRNewswire/ -- Based on its recent analysis of the early-stage breast tumor treatment device market, Frost & Sullivan recognizes Novian Health, Inc. with the 2014 North America Frost & Sullivan Award for Technology Innovation Leadership. No...
 -- Novilase minimizes the loss of surrounding breast tissues and reduces retreatment rates
Atossa Genetics Inc. (NASDAQ: ATOS) today announced that its subsidiary, The National Reference Laboratory for Breast Health, Inc., or the NRLBH, will exhibit at the upcoming 2014 Breast Cancer Symposium in San Francisco, CA, September 4-6, 2014.
SCHENECTADY, N.Y., Sept. 2, 2014 /PRNewswire/ -- SI Group, Inc. has announced that it has completed the previously announced acquisition of the Antioxidants, Ibuprofen, Propofol, and related businesses of Albemarle Corporation (NYSE: ALB). Through this acquisition, the company expands ...
SCHENECTADY, New York, Sept. 2, 2014 /PRNewswire/ -- SI Group, Inc. has announced that it has completed the previously announced acquisition of the Antioxidants, Ibuprofen, Propofol, and related businesses of Albemarle Corporation (NYSE: ALB). Through this acquisition, the company expa...
Biomerica, Inc. (OTCBB: BMRA), a global provider of advanced diagnostic products for the early detection of medical conditions, today reported net sales for the fiscal year 2014 were $5,120,451 versus net sales of $6,472,960 in fiscal 2013. Net loss was $215,660 for fiscal 2014 compare...
ROCKVILLE, Md., Sept. 2, 2014 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of novel anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and diseases, announced today positive results from its final preclinical...
SAN DIEGO, Sept. 2, 2014 /PRNewswire/ -- Turtle Beach Corporation (NASDAQ: HEAR), a leading innovator of audio products and solutions, today announced the hiring and appointment of Rodney Schutt as SVP and General Manager of HyperSound. Mr. Schutt joins the company as it prepares to la...
TORONTO AND CHICAGO, Sept. 2, 2014 /PRNewswire/ - Concordia Healthcare Corp. ("Concordia") (TSX:CXR) (OTCQX: CHEHF), a diverse healthcare company focused on legacy pharmaceutical products, orphan drugs, and medical devices for the diabetic population, today announced that its subsi...
PRINCETON, N.J., Sept. 2, 2014 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developing sev...
PETACH TIKVA, Israel, Sept. 2, 2014 /PRNewswire/ -- Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE: CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, today reported financial results for the six months ende...
SUNNYVALE, Calif., Sept. 2, 2014 /PRNewswire/ -- Cepheid (NASDAQ: CPHD) announced today the release of Xpert® Flu/RSV XC, an on-demand molecular test for rapid, accurate and reliable determination of Flu A, Flu B, and differentiation of RSV infection. The test will be marketed as a CE-...
BARCELONA, Spain, Sept. 2, 2014 /PRNewswire/ -- Janssen Research & Development, LLC (Janssen) and its development partner, Bayer HealthCare, announced today results from the X-VeRT trial, demonstrating once-daily XARELTO® (rivaroxaban) may be an alternative to vitamin K antagonists...
LONDON, Sept. 1, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:
NEW YORK, Sept. 1, 2014 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:  Early-Stage Minimally-Invasive Biomarkers in Alzheimer%s Disease: A Comprehensive Analysis and Market Study of New Developments and Opportunities, 2014
BRUSSELS, Sept. 1, 2014 /PRNewswire/ -- 0700 (CEST) – regulated information -- UCB announced today that the U.S. Food and Drug Administration (FDA) has approved a supplemental new drug application (sNDA) for VIMPAT® (lacosamide) C-V as monotherapy in the treatment of partial-onset seiz...
PARSIPPANY, N.J., Aug. 31, 2014 /PRNewswire/ -- Wockhardt Limited today announces a major boost to the New Drug Discovery program in Anti-Infective research when two of its drugs, WCK 771 and WCK 2349, received the coveted Qualified Infectious Disease Product (QIDP) status from U.S. Fo...
TARRYTOWN, New York and PARIS, Aug. 31, 2014 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi (EURONEXT: SAN and NYSE: SNY) today announced detailed positive results from four Phase 3 ODYSSEY trials of alirocumab in people with hypercholesterolemia.  Alirocumab...
PARIS and TARRYTOWN, N.Y., Aug. 31, 2014 /PRNewswire/ -- Sanofi (EURONEXT: SAN and NYSE: SNY) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced detailed positive results from four Phase 3 ODYSSEY trials of alirocumab in people with hypercholesterolemia. Alirocumab is a...
EAST HANOVER, N.J., Aug. 30, 2014 /PRNewswire/ -- Today at the European Society of Cardiology congress and published simultaneously in the New England Journal of Medicine, Novartis revealed that its investigational heart failure medicine, LCZ696, was superior to ACE-inhibitor enalapril...
NEW YORK, Aug. 29, 2014 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in InVivo Therapeutics Holdings Corp. ("InVivo" or the "Company") (OTC: NVIV) of the October 6, 2014 deadline to seek the role of lead plaintiff in a federal secu...
NEW YORK, Aug. 29, 2014 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in EDAP TMS SA ("EDAP" or the "Company") (NasdaqGM: EDAP) of the October 3, 2014 deadline to seek the role of lead plaintiff in a federal securities class action ...
WILSONVILLE, Ore., Aug. 29, 2014 /PRNewswire-iReach/ -- SAM Medical Products Implements Voluntary Recall of its Accessory (Axilla) Strap for the SAM Junctional Tourniquet. 
NEW YORK, Aug. 29, 2014 /PRNewswire/ -- Pomerantz LLP has filed a class action lawsuit against EDAP TMS S.A. ("EDAP" or the "Company") (NASDAQ: EDAP) and certain of its officers.  The class action, filed in United States District Court, Southern District of New York, and docketed under...
Following the release today of the Canada-United States Regulatory Cooperation Council (RCC) Joint Forward Plan, Russell Williams, President, Canada's Research-Based Pharmaceutical Companies (Rx&D) issued the following statement:
Following the release today of the Canada-United States Regulatory Cooperation Council (RCC) Joint Forward Plan, Russell Williams, President, Canada's Research-Based Pharmaceutical Companies (Rx&D) issued the following statement: